{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "G",
          "alt": "S",
          "position": "2019"
        },
        "variant_string_id": "LRRK2 G2019S"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in leucine-rich repeat kinase 2 (LRRK2) cause familial as well as sporadic Parkinson's disease (PD) characterized by age-dependent dopaminergic neuron (DN) degeneration. Pathogenic LRRK2 antagonizes miRNAs let-7 and miR-184*, leading to overproduction of E2F1/DP, which is critical for LRRK2 pathogenesis.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines the disease mechanism as a gain-of-function effect of LRRK2 mutations leading to miRNA pathway impairment, resulting in deregulated protein synthesis of E2F1/DP, which contributes to dopaminergic neuron degeneration in Parkinson's disease."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses reporter assays (EGFP and luciferase with let-7-binding sites) to monitor miRNA activity, co-immunoprecipitation to assess protein interactions, and translational profiling to identify mRNA targets. These assays model the impact of LRRK2 on miRNA-mediated translational repression.",
          "judgment": "Yes",
          "reasoning": "The general classes of assays (reporter assays for miRNA function, co-IP for protein interactions, and translational profiling) are relevant and widely used in the field to model molecular mechanisms of disease pathogenesis, specifically the disruption of miRNA pathways in neurodegenerative diseases like PD.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Reporter assays included controls such as wild-type LRRK2 and kinase-dead mutants (3KD). Experiments were repeated (n=3) as indicated in figure legends (e.g., Fig. 1a, 1b).",
          "judgment": "Yes",
          "reasoning": "The paper includes both normal (wild-type LRRK2) and abnormal (kinase-dead mutants) controls in the assays. Replicates are explicitly mentioned (n=3), satisfying the criteria for basic controls and experimental repetition.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "The study compares pathogenic LRRK2(G2019S) with wild-type LRRK2 and kinase-dead mutants (3KD). Other pathogenic variants like I2020T and I1915T are also tested, though their classification as known pathogenic controls without PS3/BS3 reliance is not explicitly confirmed in the paper.",
          "judgment": "No",
          "reasoning": "While multiple variants are tested, the paper does not explicitly confirm that these variants (e.g., I2020T, I1915T) reach P/LP criteria without relying on PS3 evidence. Wild-type and kinase-dead mutants serve as controls, but specific known pathogenic or benign variant controls meeting ACMG criteria are not clearly documented.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_supporting due to the clear definition of disease mechanism, relevant assay types, and presence of basic controls and replicates. However, the lack of confirmed variant controls meeting P/LP or B/LB criteria without PS3/BS3 reliance limits the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "1915"
        },
        "variant_string_id": "LRRK2 I1915T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause Parkinson's disease (PD) by antagonizing miRNAs let-7 and miR-184*, leading to overproduction of E2F1/DP, critical for LRRK2 pathogenesis and dopaminergic neuron degeneration.",
          "judgment": "Yes",
          "reasoning": "The paper explicitly describes the molecular mechanism of LRRK2 mutations, linking gain-of-function effects to miRNA pathway disruption and subsequent neuronal degeneration in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Reporter assays (EGFP and luciferase with let-7-binding sites), co-immunoprecipitation, and translational profiling were used to assess the impact of LRRK2 on miRNA-mediated translational repression and protein interactions.",
          "judgment": "Yes",
          "reasoning": "These assay types are appropriate and commonly used to investigate molecular mechanisms in neurodegenerative diseases, effectively modeling the miRNA pathway disruption central to LRRK2 pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Assays included wild-type LRRK2 and kinase-dead mutants (3KD) as controls. Replicates are mentioned (n=3) in figure legends (e.g., Fig. 1a, 2a).",
          "judgment": "Yes",
          "reasoning": "Both normal (wild-type) and abnormal (kinase-dead) controls are present, and replicates are documented, meeting the criteria for basic experimental rigor.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "Pathogenic LRRK2(I1915T) is compared with wild-type and kinase-dead mutants. Other variants (e.g., G2019S, I2020T) are tested, but their independent P/LP classification without PS3/BS3 is not confirmed.",
          "judgment": "No",
          "reasoning": "The paper lacks explicit evidence that control variants used meet P/LP or B/LB criteria independently of PS3/BS3, limiting the ability to elevate the evidence strength beyond supporting.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "LRRK2 I1915T receives a PS3_supporting rating due to a well-defined disease mechanism, appropriate assays, and basic controls/replicates. However, the absence of confirmed variant controls with independent P/LP classification restricts the strength to supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "I",
          "alt": "T",
          "position": "2020"
        },
        "variant_string_id": "LRRK2 I2020T"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Pathogenic LRRK2 mutations, including I2020T, cause PD by antagonizing miRNAs let-7 and miR-184*, resulting in overproduction of E2F1/DP, which drives dopaminergic neuron degeneration.",
          "judgment": "Yes",
          "reasoning": "The disease mechanism is clearly articulated, linking LRRK2 gain-of-function mutations to miRNA pathway impairment and neuronal degeneration in PD."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Luciferase reporter assays with let-7-binding sites were used to test the effect of hLRRK2(I2020T) on miRNA-regulated translation in HEK293T cells, alongside co-IP and translational profiling.",
          "judgment": "Yes",
          "reasoning": "The assays employed are standard in the field for assessing miRNA function and protein interactions, directly relevant to modeling LRRK2's role in PD pathogenesis.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Controls include wild-type LRRK2 and kinase-dead mutants (3KD). Replicates are noted in supplementary figures (e.g., Fig. s2a, s2b, n=3).",
          "judgment": "Yes",
          "reasoning": "The presence of both normal and abnormal controls, along with documented replicates, fulfills the requirements for basic experimental design.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "hLRRK2(I2020T) is tested alongside wild-type, kinase-dead, and other pathogenic mutants (e.g., G2019S), but independent P/LP or B/LB classification without PS3/BS3 is not specified.",
          "judgment": "No",
          "reasoning": "There is no clear documentation of variant controls meeting ACMG criteria for P/LP or B/LB without reliance on PS3/BS3, limiting the evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "LRRK2 I2020T is assigned PS3_supporting strength based on a defined disease mechanism, relevant assays, and adequate controls/replicates. The lack of confirmed variant controls with independent classification prevents a higher strength rating."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1441"
        },
        "variant_string_id": "LRRK2 R1441G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Gain-of-function mutations in LRRK2 cause PD through miRNA pathway impairment. However, hLRRK2(R1441G) had no effect on let-7 miRNA function, suggesting a different mechanism.",
          "judgment": "Yes",
          "reasoning": "The general disease mechanism for LRRK2 mutations is defined, but R1441G is noted to act through a different, unspecified mechanism, which still allows for functional assessment."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Luciferase reporter assays with let-7-binding sites tested hLRRK2(R1441G) for effects on miRNA function, showing no impact (Fig. s2b).",
          "judgment": "Yes",
          "reasoning": "The assay type is appropriate for testing miRNA pathway effects, relevant to LRRK2 pathogenesis, even if the result for R1441G was negative.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Controls include wild-type LRRK2 and kinase-dead mutants. Replicates are indicated in supplementary figures (e.g., Fig. s2b, n=3).",
          "judgment": "Yes",
          "reasoning": "Basic controls (normal and abnormal) and replicates are present, meeting the criteria for experimental rigor.",
          "next_step_or_outcome": "Proceed to Step 3c"
        },
        {
          "step_name": "Step 3c: Variant Controls",
          "extracted_paper_info": "hLRRK2(R1441G) is compared with wild-type, kinase-dead, and other pathogenic mutants, but independent P/LP or B/LB status without PS3/BS3 is not confirmed.",
          "judgment": "No",
          "reasoning": "Lack of explicit confirmation of variant controls meeting ACMG criteria without PS3/BS3 reliance limits the evidence strength.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "LRRK2 R1441G is rated as PS3_supporting due to a defined broader disease mechanism, relevant assays, and basic controls/replicates. Although it shows no effect on miRNA function, suggesting a different mechanism, the lack of confirmed variant controls caps the strength at supporting."
    },
    {
      "variant_id": {
        "Gene": "LRRK2",
        "Protein_Change": {
          "ref": "R",
          "alt": "G",
          "position": "1069"
        },
        "variant_string_id": "LRRK2 R1069G"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "LRRK2 mutations generally cause PD via miRNA pathway impairment. Transgenic flies expressing dLRRK(R1069G), equivalent to human R1441G, showed no dopaminergic neuron loss, indicating a different mechanism.",
          "judgment": "Yes",
          "reasoning": "The general mechanism for LRRK2 mutations is defined, though R1069G (fly equivalent of R1441G) does not impact the miRNA pathway, suggesting an alternative pathogenic route."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "Transgenic fly models assessed dopaminergic neuron loss for dLRRK(R1069G), showing no toxicity (Fig. s2c).",
          "judgment": "Yes",
          "reasoning": "The in vivo fly model is a relevant assay for assessing neuronal toxicity in PD, even if the specific variant shows no effect in this context.",
          "next_step_or_outcome": "Proceed to Step 3"
        },
        {
          "step_name": "Step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Controls include wild-type and other pathogenic LRRK2 variants. Replicates are implied in figure data (Fig. s2c), though not explicitly quantified for this variant.",
          "judgment": "No",
          "reasoning": "While controls are present, the paper does not explicitly state replicate numbers for R1069G-specific experiments, failing to fully meet the criteria for replicates.",
          "next_step_or_outcome": "Proceed to Step 3b"
        },
        {
          "step_name": "Step 3b: Accepted/Validated Assay",
          "extracted_paper_info": "The fly model for dopaminergic neuron loss is a standard approach in PD research, widely used and accepted in the field.",
          "judgment": "Yes",
          "reasoning": "The assay (transgenic fly model for neuronal toxicity) is a historically accepted method in PD research, satisfying the condition for a validated assay despite insufficient replicate documentation.",
          "next_step_or_outcome": "Max PS3_supporting"
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_supporting"
      },
      "overall_conclusion": "LRRK2 R1069G is assigned PS3_supporting strength due to a defined disease mechanism and use of a validated assay (fly model). Although it shows no toxicity in this context, suggesting a different mechanism, the accepted assay status and basic controls support this rating, despite lack of explicit replicate data."
    }
  ]
}